2007. REACH

OL/ IFX/pedCD/ Induc+Maintain

Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn's Disease in Children

Randomized open-label.
Aim: Safety and efficacy of IFX in paediatric CD.
Induction (w0,2,6) 5mg/kg IFX then patients responding at w10 were randomized to IFX q8 or q12 through w46.

Outcomes:
- Efficacy of induction regimen with IFX
- Clinical response and remission at w54

Results:
- Overall response to IFX w10: 88.4% clinical response;58.9% clinical remission
- W54 clinical response: 63.5% IFXq8 vs 33.3% IFXq12 : p=0.002
- W54 clinical remission: 55.8% IFXq8 vs 23.5% IFX q12; p<0.001

Conclusion:
Paediatric patients responding to induction with IFX are more likely to be in clinical response and remission at w54 when therapy was given every 8 weeks rather than 12.



Figure 2. Clinical response (decrease from baseline to week 10 in the total PCDAI score of at least 15 points and a total PCDAI score of no more than 30 points (*A*) and clinical remission (PCDAI score of 10 points or lower; (*B*) for week 10 responders at weeks 30 and 54. All randomized patients.

Hyams J et al. Gastroenterology 2007; 132:863-873